Guardion Health Sciences to Present at the H.C. Wainwright Bioconnect 2022 Virtual Conference

Rhea-AI Summary

Guardion Health Sciences (Nasdaq: GHSI) is set to present a corporate overview at the H.C. Wainwright Bioconnect 2022 Virtual Conference from January 10-13, 2022. CEO Bret Scholtes will lead the presentation, available on-demand starting January 10 at 7:00 a.m. ET. Guardion specializes in clinically supported nutrition, medical foods, and supplements aimed at aiding healthcare professionals and consumers in achieving health goals. The company emphasizes its strong scientific advisory board and ongoing developments in the clinical nutrition field.

HOUSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI), a clinical nutrition company that develops clinically supported nutrition, medical foods, and supplements, announces today that Chief Executive Officer Bret Scholtes will present a corporate overview at the H.C. Wainwright Bioconnect 2022 Virtual Conference, which is taking place on January 10 – 13, 2022.

The presentation will be available on-demand to registered attendees of the conference beginning at 7:00 a.m. ET on Monday, January 10, 2022.

Register for the conference: https://hcwevents.com/bioconnect/

About Guardion Health Sciences, Inc.

Guardion Health Sciences, Inc. (Nasdaq: GHSI), is a clinical nutrition company. Guardion’s portfolio of science-based, clinically supported nutrition, medical foods, and supplement products support healthcare professionals, their patients, and consumers in achieving health goals. Guardion’s commercial and developmental initiatives are supported by equally impressive scientific and medical advisory boards, led by seasoned business executives and physicians with many years of experience. This combination of expertise and scientific knowledge forms the foundation of Guardion’s growing position within the clinical nutrition marketplace. Information and risk factors with respect to Guardion and its business, including its ability to successfully develop and commercialize its proprietary products and technologies, may be obtained in the Company’s filings with the U. S. Securities and Exchange Commission (the “SEC”) at www.sec.gov.

Forward-Looking Statement Disclaimer

With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but are not limited to, the Company’s ability to raise sufficient financing to implement its business plan, the integration of a new management team, the integration of one or more acquisitions and targets, the impact of the COVID-19 pandemic on the Company’s business, operations and the economy in general, the Company’s ability to successfully develop and commercialize its proprietary products and technologies, and the Company’s ability to maintain compliance with Nasdaq’s listing requirements. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
CORE IR
Scott Arnold
516-222-2560
scotta@coreir.com

Media Relations Contact:
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com

FAQ

When will GHSI present at the H.C. Wainwright Bioconnect 2022 Virtual Conference?

GHSI will present at the conference from January 10-13, 2022, with the presentation available on-demand starting January 10 at 7:00 a.m. ET.

Who is presenting for GHSI at the H.C. Wainwright Bioconnect Conference?

CEO Bret Scholtes will present the corporate overview for GHSI at the conference.

What are GHSI's main products?

GHSI focuses on clinically supported nutrition, medical foods, and supplements to help healthcare professionals and consumers meet health objectives.

How can I register for the H.C. Wainwright Conference to hear GHSI's presentation?

You can register for the conference by visiting the H.C. Wainwright event site at https://hcwevents.com/bioconnect/

What is the focus of GHSI's operations?

GHSI is dedicated to developing and commercializing clinical nutrition products that support health goals, backed by a strong scientific advisory board.